Docoh
Loading...

PFE Pfizer

Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. It strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, it collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, it has worked to make a difference for all who rely on it. It routinely posts information that may be important to investors on its website at www.Pfizer.com.

Company profile

PFE stock data

(
)

Calendar

13 May 21
30 Jul 21
31 Dec 21
Quarter (USD)
Apr 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Pfizer earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.81B 1.81B 1.81B 1.81B 1.81B 1.81B
Cash burn (monthly) 5.33M 32.25M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 20.64M 124.82M n/a n/a n/a n/a
Cash remaining 1.79B 1.68B n/a n/a n/a n/a
Runway (months of cash) 335.3 52.2 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jul 21 John D Young Phantom Stock Units SSP Common Stock Grant Aquire A No No 40.09 11 440.99 52,834
15 Jul 21 Rady A Johnson Phantom Stock Units SSP Common Stock Grant Aquire A No No 40.09 4 160.36 6,610
15 Jul 21 Jennifer B. Damico Phantom Stock Units SSP Common Stock Grant Aquire A No No 40.09 31 1.24K 14,672
15 Jul 21 Albert Bourla Phantom Stock Units SSP Common Stock Grant Aquire A No No 40.09 12 481.08 88,599
13 Jul 21 Albert Bourla Phantom Stock Units SSP Common Stock Grant Aquire A No No 39.65 48 1.9K 88,595

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

64.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2584 2603 -0.7%
Opened positions 159 304 -47.7%
Closed positions 178 157 +13.4%
Increased positions 1171 1226 -4.5%
Reduced positions 1055 886 +19.1%
13F shares
Current Prev Q Change
Total value 130.1B 136.16B -4.5%
Total shares 3.59B 3.7B -2.8%
Total puts 54.02M 56.14M -3.8%
Total calls 44.1M 63.75M -30.8%
Total put/call ratio 1.2 0.9 +39.1%
Largest owners
Shares Value Change
Vanguard 450.91M $16.34B +0.7%
BLK Blackrock 405.73M $14.7B +2.2%
STT State Street 274.89M $9.96B -1.7%
Wellington Management 249.78M $9.05B +1.3%
Capital World Investors 230.09M $8.34B -13.7%
Geode Capital Management 94.15M $3.4B +4.1%
BAC Bank Of America 67.85M $2.46B -0.9%
NTRS Northern Trust 65.05M $2.36B -2.5%
BK Bank Of New York Mellon 61.94M $2.24B -4.3%
State Farm Mutual Automobile Insurance 56.54M $2.05B 0.0%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -60.3M EXIT
Capital World Investors 230.09M -36.56M -13.7%
AMP Ameriprise Financial 17.94M +9.45M +111.3%
BLK Blackrock 405.73M +8.76M +2.2%
Charles Schwab Investment Management 50.57M +8.57M +20.4%
TROW T. Rowe Price 23.27M -8.28M -26.3%
Canada Pension Plan Investment Board 13.77M +7.65M +125.2%
BEN Franklin Resources 26.55M +7.53M +39.6%
MS Morgan Stanley 46.31M -7.3M -13.6%
Two Sigma Investments 7.08M +7.08M NEW
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
7th grade Avg
New words: acetate, administered, adolescent, Amplyx, ANDA, Aug, Aurobindo, back, Baltimore, Biden, BLA, BOD, booster, castration, compromised, constraining, contraceptive, corridor, Cosmetic, Council, Cutaquig, debilitating, Dec, decided, dedicated, Dohme, Duchenne, dynamic, dystrophy, Energy, essentially, estradiol, EUA, evenly, Facebook, Feb, Fee, feedback, fit, fordadistrogene, Fosmanogepix, fungal, geopolitical, healthy, immunoglobulin, implied, institution, instrument, interpretation, intravenously, invoiced, ISDA, Israel, IVIg, Jan, justifying, Keytruda, LinkedIn, LOE, managerial, Mar, Maryland, master, Mayor, merit, movaparvovec, MTM, muscular, Myovant, norethindrone, Nov, occurrence, Oct, Octagam, PGS, Presidential, principle, proportionately, Relugolix, remittance, restated, retail, revocation, rolling, run, sasanlimab, sensitive, Sept, Sharp, sovereign, speak, sponsored, Stewardship, Surveillance, transparency, twelve, Twitter, unasserted, undergoing, undertaken, unduly, user, Uterine, vigorously, war, warrant, website, YouTube
Removed: AA, AbbVie, Abrilada, abrocitinib, ACA, accelerate, acceptable, accommodate, accounted, accretion, acid, ACIP, acquire, acquiring, adalimumab, adult, Advair, advantage, adversely, advocacy, affirmed, affordability, affordable, aggressively, Aid, Ajanta, allocated, alopecia, Amgen, AML, amplify, Amsparity, Anacor, analytical, analyze, announcement, antibody, Anticoagulant, antirheumatic, Apotex, approve, approximate, areata, Argentina, arrangement, assessed, assign, assigned, assuming, assurance, asterisk, atopic, atorvastatin, atrial, attendant, attention, automate, automation, avelumab, axial, axitinib, Bamboo, battle, BCG, began, benchmark, beta, biologic, Biotechnology, blend, Bosulif, bosutinib, BRAF, Brazil, breast, Breckenridge, bridge, broad, budget, building, burden, buy, calcium, calculate, California, calling, capacity, capsule, carcinoma, cardiomyopathy, Carolina, CDI, CDK, cell, center, cGMP, charitable, checkpoint, children, Citrate, clarifying, clarity, cleaning, clinically, closely, cloud, CML, collaborate, colorectal, column, combat, commencing, commensurate, commercialization, commercialize, commercially, commingled, commitment, committing, commonly, community, comparative, comparing, comparison, compel, compliance, comply, composed, computing, confidence, confirmed, confluence, conform, conjugate, construct, consummation, contact, contracted, contracting, controlled, conversion, converted, convertible, creating, CreditWatch, crisaborole, Crohn, curing, customary, cytarabine, Daurismo, de, debarment, decade, decline, deconsolidated, decreased, deem, defaulting, deficiency, Del, delivering, demerger, denial, depend, derive, designate, designated, designation, detected, determination, diagnosed, differentiated, difficile, dilated, directed, disability, disadvantaged, disciplined, distancing, distinct, diverse, dividing, doctor, document, domestic, domestically, doubtful, Dr, dual, easily, EBITDA, education, efficient, elaparvovec, element, eligible, eliminating, emerge, employment, enable, enabler, ending, endpoint, enhance, enrollment, ensuring, entity, equally, equate, equipment, Esteve, Eucrisa, evolving, exacerbation, exclusionary, executing, exhibit, existed, expectation, expertise, exploring, expression, extend, facilitating, fairly, family, FASB, Fast, favor, feared, feasible, fibrillation, fidanacogene, fiduciary, field, fighting, finalized, firm, firmly, fluctuate, footnote, footprint, force, formal, Fosun, free, FTC, fulfilling, fund, gene, generate, German, glasdegib, Glossary, governance, governing, GPD, grow, guarantee, half, heading, hemophilia, hepatocellular, hereditary, holding, honoring, hormone, hospitalization, Huahai, Humira, hyperinflationary, hypothetical, IBT, Immunology, import, importation, impose, inadequate, inadequately, inappropriate, incidence, inclusive, incorporate, independently, ineffective, infected, Inflammation, Inflectra, infusion, Inhub, initially, initiative, Injection, injunction, innovation, innovator, inspect, inspection, intention, interaction, interbank, intolerant, intubation, investing, Ireland, issuance, issuer, Italy, job, join, juvenile, Kerydin, kinase, lactamase, Lamin, launched, leadership, led, legislatively, leukemia, lorlatinib, lose, lost, lowered, lung, Lyme, lymphocytic, lymphoma, MabThera, maker, manager, managing, mandated, materialize, maturing, maximize, McPherson, mCSPC, MDL, medically, Medivation, methotrexate, microscopic, midpoint, mild, minimize, mixed, moderating, modification, modified, molecule, monoclonal, Moody, Morbidity, mortality, moved, mRNA, multiplying, mutation, myriad, natural, NDMA, necessarily, Neulasta, nmCRPC, notch, noted, noting, Notwithstanding, novo, OA, obligor, obtained, offered, offering, Official, oncology, opening, Opiate, opinion, opioid, opportunity, optimize, option, organize, organized, Organizing, original, outbreak, overhead, Oversight, owed, ownership, page, par, parity, PARP, pathway, paying, PCAOB, pegfilgrastim, penetration, Pensa, percent, performed, periodically, perpetual, pharmacy, physician, pilot, pivotal, plaque, pneumonia, pneumoniae, point, population, portray, positioned, post, potent, power, powerful, precipitate, preferred, preliminarily, preliminary, Premarin, prepare, prescribe, prescribing, presently, prevalent, Prevenar, preventable, preventing, Prinston, proceed, produce, profit, progressed, progression, prolonged, promotional, prophylactic, proportion, proprietary, protein, publication, purport, pursuing, put, qualified, qualify, quantifying, RA, rapid, rapidly, rare, rated, rating, rationalization, RCC, reach, reallocating, recall, receive, recognizing, recommend, recommendation, reconciliation, reconciling, recoup, recruitment, recur, redecide, redeemed, redemption, referred, refine, refocused, refund, refused, regulate, regulator, reliable, reliant, remained, Remicade, remotely, reorganized, repay, repayment, repeal, replenish, reportable, repurchase, repurchased, requirement, resolved, resource, responded, responding, responsibility, resume, reversal, Reverse, reviewed, revision, rheumatoid, ritlecitinib, Rituxan, Roche, room, satisfaction, scale, science, scope, screening, secondary, seizure, Select, selective, sharing, show, shown, side, Sildenafil, Similarly, simpler, simplify, SIP, smaller, social, software, Solco, somatrogon, Spain, specialty, specifically, speed, spend, spread, stage, stand, standalone, stayed, stemming, streamlining, strict, strongest, structured, submit, substitute, sued, suggest, Sulperazon, sum, Summarized, Sun, superior, supportable, supported, suppurativa, surface, surgical, survival, suspension, sustainable, symptomatic, system, systemic, Tadalafil, tailored, tavaborole, taxation, TCJA, TEC, territorial, test, testing, Therachon, therapy, therefrom, tiered, timeframe, today, tolerated, Track, transform, transitioning, transmission, transthyretin, travel, treating, tyrosine, UC, ultimate, unaudited, unchanged, underserved, underwritten, undue, unemployment, unmet, unpaid, unprecedented, unqualified, unreasonable, unrecognized, unsecured, unsuccessful, untreated, upgraded, uptake, urothelial, USP, utilized, utilizing, vacated, vaccinate, vaccination, VAI, Valneva, valuation, varenicline, variation, VBP, Venezuela, venture, vi, viable, vii, viii, ViiV, violate, visit, Viwit, volatile, voluntary, voted, Vyndamax, Vyndaqel, wake, warfarin, warning, Weekly, widespread, withdraw, withdrawal, Wixela, workforce, WRDM, Zavicefta, Zhejiang, Zithromax

Patents

APP
Utility
Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
29 Jul 21
Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
APP
Utility
Solid Dispersions of a ERB2 (HER2) Inhibitor
22 Jul 21
A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein.
GRANT
Utility
Diacylglycerol acyl transferase 2 inhibitor
20 Jul 21
Inventors: David James Edmonds, Kevin James Filipski, Kentaro Futatsugi, Michelle Renee Garnsey, Jack Chang Hung Lee, Daniel Jonathan Smaltz
GRANT
Utility
Solid dosage forms of palbociclib
20 Jul 21
The present invention relates to solid dosage forms of palbociclib comprising a water-soluble acid.
GRANT
Utility
Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
20 Jul 21
The present disclosure relates to: a) a crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier; and c) methods of treating a tumor, a cancer, or a Rasopathy disorder by administering the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof.